108 related articles for article (PubMed ID: 21449876)
1. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
Simoens SR
Med J Aust; 2011 Jan; 194(1):52-3; author reply 53-4. PubMed ID: 21449876
[No Abstract] [Full Text] [Related]
2. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
Clarke PM; Fitzgerald EM
Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715
[TBL] [Abstract][Full Text] [Related]
3. Generic atorvastatin and health care costs.
Kennally WC
N Engl J Med; 2012 Apr; 366(15):1451; author reply 1451. PubMed ID: 22494136
[No Abstract] [Full Text] [Related]
4. The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure.
Clarke PM
Med J Aust; 2013 Mar; 198(5):260. PubMed ID: 23496399
[No Abstract] [Full Text] [Related]
5. Generic atorvastatin and health care costs.
Jackevicius CA; Chou MM; Ross JS; Shah ND; Krumholz HM
N Engl J Med; 2012 Jan; 366(3):201-4. PubMed ID: 22149736
[No Abstract] [Full Text] [Related]
6. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Comment.
Bulfone L
Med J Aust; 2010 Aug; 193(3):186-7; author reply 187. PubMed ID: 20678054
[No Abstract] [Full Text] [Related]
7. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
8. Statin utilisation--recognising the role of the invisible hand.
Minhas R
Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
[No Abstract] [Full Text] [Related]
9. Zero copayment for generic statins could save billions.
Manag Care; 2013 Mar; 22(3):44. PubMed ID: 23610806
[No Abstract] [Full Text] [Related]
10. How to lose a billion pounds.
Moon JC; Bogle RG
Int J Clin Pract; 2007 Jan; 61(1):2-3. PubMed ID: 17229170
[No Abstract] [Full Text] [Related]
11. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
12. Switching statins: cost of simvastatin is overestimated.
Ashcroft JS
BMJ; 2006 Jun; 332(7556):1512. PubMed ID: 16793831
[No Abstract] [Full Text] [Related]
13. The impact of generic reference pricing interventions in the statin market.
Puig-Junoy J
Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
[TBL] [Abstract][Full Text] [Related]
14. Has cost inhibited the uptake of more potent statins in England?
Chapman SR; Fitzpatrick RW; Aladul MI
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):984-991. PubMed ID: 28612964
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerosis patents: clues to the next drug generation.
Suckling KE
Biotechnology (N Y); 1994 Dec; 12(13):1379-80. PubMed ID: 7765570
[No Abstract] [Full Text] [Related]
16. Focus on the patent cliff to maximize generic savings.
Cahn L
Manag Care; 2012 Nov; 21(11):28-32. PubMed ID: 23236715
[No Abstract] [Full Text] [Related]
17. Switching statins.
Moon JC; Bogle RG
BMJ; 2006 Jun; 332(7554):1344-5. PubMed ID: 16763226
[TBL] [Abstract][Full Text] [Related]
18. Best medicines for less: we compare drugs for what ails America.
Consum Rep; 2008 Jan; 73(1):27-9. PubMed ID: 18488284
[No Abstract] [Full Text] [Related]
19. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
